Journal
LANCET ONCOLOGY
Volume 17, Issue 2, Pages E62-E69Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(15)00388-5
Keywords
-
Categories
Funding
- LYRIC [INCa_4664]
- Project EuroSARC [FP7-278742]
- NetSARC
- Reseau de Reference en Pathologie des Sarcomes
- Labex DevweCan [ANR-10-LABX-0061]
Ask authors/readers for more resources
Rare cancers are defined by an incidence of less than six per 100 000 people per year. They represent roughly 20% of all human cancers and are associated with worse survival than are so-called frequent tumours, because of delays to accurate diagnosis, inadequate treatments, and fewer opportunities to participate in clinical trials (because of a paucity of dedicated trials from both academic and industrial sponsors). In this Series paper, we discuss how these challenges can be addressed by research consortia and suggest the integration of these consortia with reference networks, which gather multidisciplinary expert centres, for management of rare tumours.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available